

Development and Validation of RP-HPTLC Method for Determination of Tigecycline hydrochloride in Bulk and its Formulation

Aayesha Ansari¹, Rashid Ansari², Mohammad Mojeeb Khan^{1*}.

1 Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India

2 Department of Pharmacology, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule, Maharashtra. 424001

Date of Submission: 15-08-2024

Date of Acceptance: 25-08-2024

ABSTRACT: Tigecycline is a semisynthetic intravenous antibiotic. In this study a new simple, accurate, precise and selective high performance thin layer chromatographic (HPTLC) method has been developed and validated for the determination of Tigecycline hydrochloride in bulk and its formulation. Tigecycline is a semisynthetic intravenous antibiotic. Chromatographic separation was performed on aluminum plate percolated with RP-18 Silica Gel 60 F25S using, Methanol: Acetonitrile: Water (3: 3: 4 v/v/v) as mobile phase & 1ml Triethylamine as a plate modifier. Densitometry scanning done at 245 nm. This system was found to give compact spot for Tigecycline (Rf value = 0.7 ± 0.02). The calibration curve was found to be linear between 1000- 6000 ng/band. The limit of detection and quantitation were found to be 0.7 ng/band and 2.3 ng /band respectively. The proposed method can be applicable for the estimation of Tigecycline during stability studies. **KEYWORDS:** HPTLC, Tigecycline hydrochloride, Method development, Validation

I. INTRODUCTION

Tigecycline, a member of the glycycline class of antimicrobial agents, carries a glyclamido moiety attached to the 9-position of minocycline (Grayson et al., 2017; Yaghoubi et al., 2022), which is a semisynthetic intravenous antibiotic (Groman, 2015). Tigecycline binds to bacterial 30S ribosomal subunit to inhibit protein synthesis in bacteria, and has shown a broad-spectrum of antibacterial activity against anaerobic bacteria, Gram-negative, and Gram-positive including methicillin-resistant *Staphylococcus aureus* (Bradford, 2004). It is indicated for the treatment of complicated skin

and skin-structure infections and complicated intra-abdominal infections (Townsend et al., 2007). Tigecycline is a new glycycline with broad spectrum antibiotic activity. It is chemically (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethyl amino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide. Chemical structure of Tigecycline is shown in Figure 1.

A review of the literature reveals the analytical procedures used to determine TGN. Quantification of Tigecycline in Bulk and its Dosage Form Using a Stability Indicating Method, ultrafast LC for estimation of Tigecycline in injection formulation, and UPLC for estimation of Tigecycline in Human plasma were all done using high performance liquid chromatography. Few Analytical studies performed for determination of Tigecycline using UV spectroscopy.

However, no HPTLC method has been produced to date. Therefore, attempts were made to develop and validate a cost effective, economical and environment friendly method for the determination of Tigecycline. In RP-HPTLC technique, the mobile phase was prepared by the simple mixture of water and methanol (green solvent) as compared to normal phase HPTLC technique. The adaptation of reverse phase methodology over normal phase helped in avoiding the non-polar fractions from the sample in the TLC, which gives a very clear elution pattern. The aim of the practical is to develop simple, accurate and precise chromatographic methods for Tigecycline in bulk. These methods are developed and validated as per ICH guidelines.

In analytical method lowest amount of sample that can be detected known as Limit of Detection (LOD) whereas the lowest amount of sample that can be quantified known as Limit of Quantification (LOQ). The detection was calculated by $(3.3 \times A.S.D)/b$ and Quantification limit was calculated by $(10 \times A.S.D)/b$ where, b, correspond to graph slope.

III. RESULT AND DISCUSSION

After the development of novel method the different analytical prospects are achieved, as discussed follows.

Optimization and development of TLC

Initially, Methanol and Acetonitrile solvent were chosen on the basis of drug polarity, then the Water is added, in varying ratios was tested but tailing was observed, was overcome by Triethylamine used as modifier. In the end, the mobile phase Methanol: Acetonitrile: Water (3: 3:

4 v/v/v) gave good, sharp, well resolved and symmetrical peak with Rf value of 0.70 ± 0.02 for Tigecycline (TGN). The mobile phase containing chamber was saturated for 20 min at room temperature and plate activated at 5 min.

Study of calibration curve.

The developed method of linearity was linear in range of 1000 – 6000 ng/band (fig.2). It shows the good linear relationship with applied sample concentration. The correlation coefficient was found to be 0.998 with linear equation of $0.5680x + 1868.6$ (table 1).

Precision

The precision was described by relative standard deviation (RSD %). The intraday and inter-day precision RSD value was found to be 0.59-1.10 and 0.80-1.7 respectively (table 2).




Figure 2: Densitogram of TGN in optimized mobile phase




Figure 3: Linearity of TGN

Accuracy or recovery

The recovery studies by analytical technique of pre-analyzed sample spiked with standard TGN is known as recovery or accuracy.

The results of accuracy were shown in table. The % recovery was found to be 99.94 -100.19 % (Table 3)

Table 1: Results of validation parameter (as per ICH guidelines) for TGN

Parameters	Result
Linearity	0.998
% RSD (precision)	< 2 %
Recovery	100.08
Limit of detection	0.7 ng/band
Limit of quantification	2.328 ng/band
Robustness	Method was robust

Table 2: Precision Studies

Concentration	Intra-day %RSD (should be <2)	Inter-day %RSD (should be <2)
1400	0.96	1.38
2100	1.1	0.80
2800	0.58	1.73

Table 3: Result of accuracy study

Drug	% amount of standard drug added	% Recovery	% RSD
TGN	80	100.18	0.43
	100	100.11	0.26
	120	99.94	0.10

Robustness

For developed HPTLC method, the standard deviation and percentage of RSD of the robustness parameter was calculated. The results of robustness given in (table 4)

Limit of detection and limit of quantitation For the developed HPTLC method, the limit of detection and limit of quantification were found to be 0.76 ng/ml and 2.3 ng/ml, respectively.

Table 4 .Robustness Studies

Robustness parameter	RF	% RSD
Change in Mobile Phase Composition (Methanol: Acetonitrile: Water: trimethylamine)		
4:4:2:0.1 v/v/v	0.73	1.21
5: 1: 4:0.1 v v/v/v	0.69	1.1
3.5: 3.5: 3 :0.1v/v/v/v	0.72	1.3
Mean	0.71	1.20
Mobile Phase Volume		
9 mL	0.72	1.68
10 mL	0.68	1.33
11 mL	0.71	0.94
Mean	0.70	1.31
Duration of saturation		
15 min	0.72	1.56
20 min	0.74	1.14
25 min	0.68	0.68
Mean	0.71	1.12

IV. CONCLUSION

The developed TLC/Densitometry method is a simple, accurate, and repeatable quantitative analysis for estimating Tigecycline hydrochloride in pharmaceutical formulation. The procedure has been validated as per ICH guidelines Q2 (R1). The method is precise and there is no intervention from any of the sample in the study. It can be concluded that the system established offers many advantages such as quick, simple.

Mobile phase and simple preparation measures, more sensitive and comparative short runtime.

Source of Funding

The authors would like to thank the ‘Department of Science and Technology-FIST, Govt. of India’ (Grant No. SR/FST/College- 2018/268) for funding the project.

Conflict of Interest

None.

Acknowledgement

The authors would like to thank the 'Department of Science and Technology-FIST, Govt. of India' (Grant No. SR/FST/College-2018/268) for funding the project. The authors are thankful to Dr. S. J. Surana Principal R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, for providing essential laboratory facilities and grateful to BDR Pharmaceuticals International PVT. LTD, Vadodara, India for providing Tigecycline hydrochloride as a gift sample.

REFERENCES

- [1]. Bradford, P.A., 2004. Tigecycline: a first in class glycycline. Clin. Microbiol. Newsl. 26, 163–168. <https://doi.org/10.1016/j.clinmicnews.2004.10.001>
- [2]. Grayson, M.L., Cosgrove, S., Crowe, S., Hope, W., McCarthy, J., Mills, J., Mouton, J.W., Paterson, D. (Eds.), 2017. Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set, 7th ed. CRC Press, Boca Raton. <https://doi.org/10.1201/9781498747967>
- [3]. Greer, N.D., 2006. Tigecycline (Tygacil): the first in the glycycline class of antibiotics. Proc. Bayl. Univ. Med. Cent. 19, 155–161.
- [4]. Groman, R.P., 2015. Chapter 181- Miscellaneous Antibiotics, in: Silverstein, D.C., Hopper, K. (Eds.), Small Animal Critical Care Medicine (Second Edition). W.B. Saunders, St. Louis, pp.944–949. <https://doi.org/10.1016/B978-1-4557-0306-7.00181-1>
- [5]. Townsend, M.L., Pound, M.W., Drew, R.H., 2007. Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections. Ther. Clin. Risk Manag. 3, 1059–1070.
- [6]. Yaghoubi, S., Zekiy, A.O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., Maleki, F., 2022. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur. J. Clin. Microbiol. Infect. Dis. 41, 1003–1022. <https://doi.org/10.1007/s10096-020-04121-1>
- [7]. K Bhavyasri, C Mounik. et al ,Method Development, Validation And Forced Degradation Studies For Determination Of Tigecycline In Bulk And Pharmaceutical Dosage Form Using UV .
- [8]. AB Chauhan, et al, Area Under The Curve Spectrophotometric Method For Determination Of Tigecycline In Pharmaceutical *Formulation
- [9]. Thien-Ly Doan, PharmD1; Horatio B. Fung, PharmD, BCPS2; Dhara Mehta, PharmD3; and Paul E Riska, MD 4 "Tigecycline: A Glycycline Antimicrobial Agent"
- [10]. Sagar Suman Panda* and B.V.V. Ravi Kuma" Development and Validation of Spectrophotometric and Liquid Chromatographic Methods for Estimation of Tigecycline in Injections."
- [11]. H. OKA and K. UNO .K-I. Harada, Y. Kaneyama and M. Suzuki. Simple method for the analysis of tetracyclines on silica gel high-performance thin-layer plates.
- [12]. Thien-Ly Doan, PharmD1; Horatio B. Fung, PharmD, BCPS2; Dhara Mehta, PharmD3; and Paul E Riska, MD 4 "Tigecycline: A Glycycline Antimicrobial Agent"
- [13]. Sagar Suman Panda* and B.V.V. Ravi Kuma" Development and Validation of Spectrophotometric and Liquid Chromatographic Methods for Estimation of Tigecycline in Injections."
- [14]. International Conference on Harmonization Guideline on Validation of Analytical Procedures (2005) Text and Methodology: Q2 (R1). Available from: <https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf>.